journal article·2021-09Open access

Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID‐19 Vaccines

Thibault Colombani, Loek J. Eggermont, Zachary J. Rogers, Lindsay G. A. McKay, Laura E. Avena, Rebecca I. Johnson, Nadia Storm, Anthony Griffiths, Sidi A. Bencherif

Advanced Science· Volume 8· Issue 18

Abstract

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented global health crisis, resulting in a critical need for effective vaccines that generate protective antibodies. Protein subunit vaccines represent a promising approach but often lack the immunogenicity required for strong immune stimulation. To overcome this challenge, it is first demonstrated that advanced biomaterials can be leveraged to boost the effectiveness of SARS‐CoV‐2 protein subunit vaccines. Additionally, it is reported that oxygen is a powerful immunological co‐adjuvant and has an ability to further potentiate vaccine potency. In preclinical studies, mice immunized with an oxygen‐generating coronavirus disease 2019 (COVID‐19) cryogel‐based vaccine (O2‐CryogelVAX) exhibit a robust Th1 and Th2 immune response, leading to a sustained production of highly effective neutralizing antibodies against the virus. Even with a single immunization, O2‐CryogelVAX achieves high antibody titers within 21 days, and both binding and neutralizing antibody levels are further increased after a second dose. Engineering a potent vaccine system that generates sufficient neutralizing antibodies after one dose is a preferred strategy amid vaccine shortage. The data suggest that this platform is a promising technology to reinforce vaccine‐driven immunostimulation and is applicable to current and emerging infectious diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Immunotherapy and Immune Responses · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering Northeastern University Boston MA 02115 USA

Department of Microbiology and National Emerging Infectious Diseases Laboratories Boston University School of Medicine Boston MA 02118 USA

Department of Bioengineering Northeastern University Boston MA 02115 USA

Harvard John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA

Biomechanics and Bioengineering (BMBI) UTC CNRS UMR 7338 University of Technology of Compiègne Sorbonne University Compiègne 60203 France

Funding

Northeastern University · National Science Foundation · King Abdulaziz City for Science and Technology · National Institutes of Health

References (44)

Show source-provided references
1. 10.1016/S1473-3099(20)30120-110.1016/S1473-3099(20)30120-1 ↗
2. 10.1016/j.mayocp.2020.04.02710.1016/j.mayocp.2020.04.027 ↗
3. 10.1001/jama.2019.2015310.1001/jama.2019.20153 ↗
4. 10.1001/jama.2020.1283910.1001/jama.2020.12839 ↗
5. 10.1038/s41577-020-00434-610.1038/s41577-020-00434-6 ↗
6. 10.1016/j.prrv.2020.06.01010.1016/j.prrv.2020.06.010 ↗
7. 10.1007/s40475-020-00201-610.1007/s40475-020-00201-6 ↗
8. 10.1126/science.abb892310.1126/science.abb8923 ↗
9. Pfizer‐BioNTech COVID‐19 Vaccine | FDA. Available at:https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine. Accessed: 21st December 2020.
10. Moderna COVID‐19 Vaccine | FDA. Available at:https://www.fda.gov/emergency-preparedness-and-response/coronavirusdisease-2019-covid-19/moderna-covid-19-vaccine. Accessed: 21st December 2020.
11. 10.1002/cmdc.20120048710.1002/cmdc.201200487 ↗
12. 10.3389/fimmu.2020.0154710.3389/fimmu.2020.01547 ↗
13. Sanofi and GSK announce a delay in their adjuvanted recombinant protein‐based COVID‐19 vaccine programme to improve immune response in the elderly | GSK. Available at:https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-adelay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/. Accessed: 21st December 2020.
14. 10.1056/NEJMoa202692010.1056/NEJMoa2026920 ↗
15. 10.1038/natrevmats.2016.7110.1038/natrevmats.2016.71 ↗
16. 10.1073/pnas.121151610910.1073/pnas.1211516109 ↗
17. 10.1002/adhm.20170146910.1002/adhm.201701469 ↗
18. 10.1073/pnas.111356010910.1073/pnas.1113560109 ↗
19. 10.3390/biomedicines602005610.3390/biomedicines6020056 ↗
20. 10.18632/oncotarget.2660810.18632/oncotarget.26608 ↗
21. 10.1016/j.it.2019.06.00410.1016/j.it.2019.06.004 ↗
22. 10.1126/scitranslmed.abc353910.1126/scitranslmed.abc3539 ↗
23. 10.1038/s41591-020-0897-110.1038/s41591-020-0897-1 ↗
24. 10.1016/j.immuni.2020.07.00510.1016/j.immuni.2020.07.005 ↗
25. 10.1189/jlb.3RU0316-144R10.1189/jlb.3RU0316-144R ↗
26. 10.1038/ncomms855610.1038/ncomms8556 ↗
27. 10.1158/1078-0432.CCR-08-052610.1158/1078-0432.CCR-08-0526 ↗
28. 10.1126/scitranslmed.300035910.1126/scitranslmed.3000359 ↗
29. 10.1002/eji.20032403210.1002/eji.200324032 ↗
30. 10.1038/cmi.2017.10510.1038/cmi.2017.105 ↗
31. 10.1126/scitranslmed.aaa126010.1126/scitranslmed.aaa1260 ↗
32. 10.1002/adfm.20210223410.1002/adfm.202102234 ↗
33. 10.1016/j.tibtech.2019.09.00810.1016/j.tibtech.2019.09.008 ↗
34. 10.1016/j.addr.2020.06.01910.1016/j.addr.2020.06.019 ↗
35. 10.1080/14760584.2019.157821610.1080/14760584.2019.1578216 ↗
36. 10.1073/pnas.160605011310.1073/pnas.1606050113 ↗
37. 10.1186/s40425-019-0716-810.1186/s40425-019-0716-8 ↗
38. A. N.Honko N.Storm D. J.Bean J.Henao Vasquez S. N.Downs A.Griffiths Rapid Quantification and Neutralization Assays for Novel Coronavirus SARS‐CoV‐2 Using Avicel RC‐591 Semi‐Solid Overlay2020 2020050264https://doi.org/10.20944/preprints202005.0264.v1.10.20944/preprints202005.0264.v1 ↗
39. 10.1002/eji.20032473610.1002/eji.200324736 ↗
40. 10.1038/s41565-020-0737-y10.1038/s41565-020-0737-y ↗
41. 10.1038/s41590-017-0007-910.1038/s41590-017-0007-9 ↗
42. 10.1128/CMR.00023-0710.1128/CMR.00023-07 ↗
43. 10.1111/ajt.1406910.1111/ajt.14069 ↗
44. 10.1016/j.xphs.2020.12.00610.1016/j.xphs.2020.12.006 ↗